RC June

Debate: BTK Inhibitors vs Bendamustine-Rituximab (BR) as Primary Therapy - BTK

Debate Speaker(s)

• 

  Jeffrey Matous, MD

  CBCI- Colorado Blood Cancer Institute
  Denver, Colorado